# Mitazalimab

Source: https://onco.cc/drugs/mitazalimab/  
OnCo record `mitazalimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mitazalimab is an antibody-drug conjugate from Alligator Bioscience AB, in registered phase 2 trials for pancreatic ductal adenocarcinoma.

## Summary

Mitazalimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Alligator Bioscience AB, in pancreatic ductal adenocarcinoma. An antibody-drug conjugate, as described in the registry record: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: ADC-1013, JNJ-64457107
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Antibody-drug conjugate
- Mechanism: An antibody-drug conjugate, as described in the registry record: an antibody against a tumour surface protein carries a cytotoxic payload into the cell.

## Sources

- ClinicalTrials.gov: trials of Mitazalimab: https://clinicaltrials.gov/search?intr=Mitazalimab

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- trials: [Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients](https://onco.cc/trials/nct04888312/)

---
JSON: https://onco.cc/api/v1/entities/mitazalimab.json